AXLRx Book a callCommission
Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Priyanka

Analyst · Immunology · Oncology · Rare Disease · Metabolic · Pulmonology

P

Priyanka is an Analyst at AXLRx, authoring disease-landscape and patient-flow briefs. She assembles the epidemiology and diagnostic pathway for each indication from primary sources, applying the verify-or-drop standard so every figure traces to a live document. Her focus is rare and specialty indications.

Analyses reviewed (94)

CI · US US Atopic Dermatitis Competitive Intelligence Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs. PFM · US US NSCLC Patient Flow Model Incidence-to-eligible NSCLC funnel by cohort with sourced conversion assumptions and a share waterfall. DL · US US PNH Disease Landscape PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres. CI · US US Hereditary Angioedema Competitive Intelligence The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field. P&HTA · US US IgA Nephropathy Payer & HTA US payers gate the five FDA-approved IgAN therapies on biopsy, proteinuria and RAS-blockade step-through. The Filspari REMS, Part D routing and the ICER 2026 assessment set the rest of the access path. DL · US US Myasthenia Gravis Disease Landscape Neuromuscular-junction autoantibody biology, the AChR/MuSK/seronegative split, and the crisis burden that defines US gMG. DL · US US Cold Agglutinin Disease Disease Landscape Cold agglutinin disease is a rare classical-complement autoimmune haemolytic anaemia driven by cold-reactive IgM. This separates primary CAD from cold agglutinin syndrome and sizes the US haemolysis burden. P&HTA · US US Cold Agglutinin Disease Payer & HTA Sutimlimab (Enjaymo) is a ~$260K+/year Part B IV biologic in a few-thousand-patient population — and not cost-effective at the current price. DL · US US Pompe Disease Disease Landscape GAA-deficiency biology, the LOPD-versus-IOPD split, the years-long diagnostic delay, and newborn screening across the US Pompe population. P&HTA · US US Pompe Disease Payer & HTA Pompe ERT costs near $400,000 a year in Part B, and remains the only major rare-disease ERT category ICER has never reviewed. Pombiliti + Opfolda splits into two simultaneous prior authorisations across Part B and Part D. CI · US US Fabry Disease Competitive Intelligence Pegunigalsidase now challenges Fabrazyme's two-decade lead in US Fabry disease. Two IV enzyme replacement therapies meet an oral chaperone only ~35–50% of patients can take. DL · US US MASH Disease Landscape The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool. DL · US US Type 2 Diabetes Disease Landscape 38.4M US adults, an 8.7M undiagnosed pool, and complication burden driving GLP-1 and SGLT2 organ-protection strategy. DL · US US Obesity Disease Landscape US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage. P&HTA · US US COPD Payer & HTA COPD access is a pharmacy-benefit story: inhalers and biologics run through Medicare Part D and commercial PBMs, not medical coverage. Step edits gate the base, an eosinophil threshold gates the biologic, and the IRA is reshaping both price exposure and negotiation risk. CI · US US Breast Cancer HR+/HER2- Competitive Intelligence Only ribociclib has posted consistent overall-survival wins in the three-way first-line CDK4/6 contest. MONALEESA-2 showed 63.9 versus 51.4 months (HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker. CI · UK UK ATTR Amyloidosis Competitive Intelligence Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser. CI · GCC GCC ATTR Amyloidosis Competitive Intelligence ATTR-CM in the GCC is a pre-commercial opportunity gated by diagnosis, not by drug access. Tafamidis is SFDA-registered and tender-priced 80-90% below US list, but Tc-PYP scintigraphy runs at fewer than 8 centres. LR · UK UK Hereditary Angioedema Launch Readiness Lanadelumab leaves the never-prophylaxed UK HAE population open. This sizes the PAS discount needed to clear NICE's standard TA bar, and the donidalorsen clock a fast-moving competitor is running against you. CI · UK UK IgA Nephropathy Competitive Intelligence IgAN doesn't qualify for the ultra-rare HST track, so both novel agents must clear the standard £20,000-30,000/QALY bar. Both sit in Named Patient access ahead of their NICE decisions. CI · UK UK Myasthenia Gravis Competitive Intelligence No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid. LR · UK UK Myasthenia Gravis Launch Readiness NICE's terminated eculizumab appraisal for gMG remains the price precedent every new asset must clear. 2,000-3,000 refractory patients have no NICE-commissioned biologic option, and the IVIg-offset economics decide whether a launch is viable. LR · US US Sickle Cell Disease Launch Readiness Two withdrawals opened a 55,000–65,000-patient white space in Sickle Cell Disease — speed, not differentiation, is the binding constraint. CI · GCC GCC Sickle Cell Disease Competitive Intelligence GCC carries one of the highest per-capita SCD burdens globally: ~140,000 patients in Saudi Arabia alone. Both novel disease-modifiers hit regulatory trouble in 2023-2024, leaving a 25-year-old generic as the only agent with a stable market position. CI · GCC GCC Fabry Disease Competitive Intelligence GCC is a two-ERT Fabry market, with agalsidase alfa via the EMA pathway alongside agalsidase beta. Migalastat's oral advantage, covering 35-50% of patients, is bottlenecked by the single GCC lab that can run the amenable-mutation assay. PFM · US US Myasthenia Gravis Patient Flow Model 100,000-200,000 US gMG patients narrow to a 4,000-6,000 on-FcRn-therapy pool, and 1,200-2,100 of them remain inadequately controlled despite treatment. LR · FR FR PNH Launch Readiness Iptacopan reached French PNH patients through early access, before EU marketing authorisation took effect. HAS granted accès précoce two weeks ahead of it. Any new PNH entrant must be dossier-ready for this track before, not after, EU approval. DL · UK UK Spinal Muscular Atrophy Disease Landscape The UK ran Europe's first national SMA newborn-screening programme. All three therapies are NICE-recommended with commercial arrangements, across a living UK cohort of ~1,000 patients in four disease types. PFM · UK UK Fabry Disease Patient Flow Model 700-900 NHS-diagnosed Fabry patients split cleanly by therapy. Roughly 600 are on enzyme replacement and about 200, or 25%, on oral migalastat, with free NHS cascade testing adding 3-4 diagnosed relatives per index case. DL · UK UK PNH Disease Landscape Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture. PFM · US US Spinal Muscular Atrophy Patient Flow Model 8,000-10,000 US SMA patients split roughly 60/27/13/under 5 percent across Types 1-4. The 500-700-patient Zolgensma cohort is what this funnel validates against. P&HTA · GCC GCC Sickle Cell Disease Payer & HTA The GCC's largest rare-disease programme by patient volume sits in a commercial vacuum. Crizanlizumab and voxelotor are both withdrawn, leaving 8,000-10,000 NPHC-managed SCD patients ahead of 2025-26 gene therapy registration. LR · GCC GCC Pompe Disease Launch Readiness A new-entrant ERT cannot compete on NPHC-covered alglucosidase alone. The constraint is the NPHC step-edit plus Sanofi's entrenched home-infusion relationship at KFSH&RC, which any entrant must replicate from a standing start. LR · US US Gaucher Disease Launch Readiness Five approved Type 1 Gaucher therapies treat the body, not the brain. A genotype gate locks a meaningful share of the highest-prevalence population out of the only oral option, and a Phase 3 gene therapy trial is now racing to close that gap. PFM · GCC GCC Hereditary Angioedema Patient Flow Model Epidemiology projects 1,200-1,500 GCC HAE patients; the GCC allergy society's own case registry counts only 400-600. The gap is not a contradiction, it is the diagnostic-capacity constraint of just 6-10 specialist physicians across all six states. PFM · UK UK PNH Patient Flow Model ~600-750 UK PNH patients are on active complement-inhibitor therapy against a reconciled total prevalence near 1,500. The other 750-900 are monitored-only or undiagnosed, and this model sizes the gap. PFM · UK UK Pompe Disease Patient Flow Model 350-450 UK Pompe disease patients, of whom roughly 200 form the registry-confirmed cohort. One in four long-term ERT patients is not holding stable, the segment this model is built to size. PFM · FR FR PNH Patient Flow Model France's PMSI hospital database counts 897 PNH patients over five years; Orphanet's older estimate puts national prevalence at 850-1,000. Only 270 of them, per the manufacturer's own estimate, are eligible for a second-line oral agent. LR · GCC GCC Sickle Cell Disease Launch Readiness GCC SCD is the region's largest rare-disease market at 200,000-250,000 patients, with no novel SFDA-registered therapy. Post-withdrawal, the binding constraint is price, not competition or diagnosis. PFM · GCC GCC Pompe Disease Patient Flow Model 400-600 GCC Pompe disease patients, of whom 200-300 are on enzyme replacement therapy. Just 40-60, patients with FVC decline despite alglucosidase already on home ventilation, are the segment this model is built to size. DL · UK UK Myasthenia Gravis Disease Landscape A ~4,000-patient UK gMG treatment gap remains unresolved. Efgartigimod's June 2025 NICE rejection (TA1069) left it open, against NHS neuromuscular network diagnostics. KOL · GCC GCC Hereditary Angioedema KOL Mapping KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it. P&HTA · UK UK ATTR Amyloidosis Payer & HTA NICE rejected tafamidis for ATTR-CM in May 2021 (TA696) and recommended it in June 2024 (TA984). Acoramidis (TA1121, January 2026) and vutrisiran (TA868 for ATTR-PN, TA1115 for ATTR-CM) complete the UK amyloidosis market. LR · GCC GCC IgA Nephropathy Launch Readiness No novel IgA nephropathy agent is SFDA-registered in the GCC. First-mover filing, not clinical differentiation, decides which drug becomes the de-facto standard. MSM · US US Fabry Disease Market Sizing Model Roughly 5,000-10,000 diagnosed US Fabry patients split first by GLA amenability, with 35-50% oral-eligible. ADA status narrows that to a precise 200-400 patient addressable niche, which a Fabrazyme-anchored $250-350K WAC makes commercially calculable. HTA · UK UK Myasthenia Gravis HTA Strategy Model NICE has never modelled a cost-per-QALY for a myasthenia gravis biologic. Eculizumab's appraisal (TA636) closed before a dossier was submitted; efgartigimod's (TA1069) closed on evidence gaps, not a quantified ICER breach. A new entrant inherits no reusable comparator or price benchmark from either. HTA · UK UK Dravet Syndrome HTA Strategy Model Both existing Dravet therapies cleared NICE's standard Technology Appraisal, not the ultra-rare Highly Specialised Technology route. A new entrant's WAC, PAS, and stakeholder-engagement calendar all need to be built against that lower cost-effectiveness bar, with soticlestat's 2026-27 appraisal setting the clock. LR · GCC GCC ATTR Amyloidosis Launch Readiness No ATTR-CM treatment is SFDA-registered in the GCC, and the binding constraint is diagnosis, not competition. Without Tc-PYP expansion beyond four centres, a first-mover drug has almost no diagnosed patients to treat. PSM · GCC GCC Spinal Muscular Atrophy Pricing Strategy Model NPHC's negotiated Zolgensma price runs $1.5-1.8M against $2.125M US list. But the real mechanism is a 24-month motor-milestone rebate, the same structure now anchoring risdiplam and nusinersen pricing across the Gulf. LR · UK UK Spinal Muscular Atrophy Launch Readiness A mature three-drug NICE framework leaves no room for parity entry in UK SMA. The Zolgensma-attenuation and Type 4 adult niches are unserved, and NHS gene therapy centre capacity constrains every new entrant. PSM · GCC GCC Hereditary Angioedema Pricing Strategy Model Lanadelumab tenders at SAR 300,000-400,000 a year, but NPHC has no routine formulary price at all. Access runs through an individual-case bar only 30-40% of submissions clear, while private VHI approves at a materially lower documentation threshold. PFM · US US Fabry Disease Patient Flow Model 5,000-10,000 diagnosed US classic Fabry patients face a 35-50% amenable-mutation gate to oral therapy. The treated population is still 60-65% on enzyme replacement. This funnel starts at diagnosis because no defensible undiagnosed estimate exists yet. PFM · UK UK Myasthenia Gravis Patient Flow Model The broader estimate puts 12,000-15,000 UK patients with generalised myasthenia gravis. About 4,000 have moderate-severe disease and 2,000-3,000 are refractory, with no NICE-recommended novel agent for any of them. PFM · UK UK Dravet Syndrome Patient Flow Model 2,000-2,500 UK Dravet patients, of whom 400-500 are SCN1A-confirmed in genetic registries. 600-900 remain inadequately controlled on cannabidiol plus fenfluramine. DL · UK UK Sickle Cell Disease Disease Landscape The UK has Europe's largest SCD population at 15,000–17,000 patients. Newborn screening has made diagnosis near-universal since 1999, and NICE's recommendation of Casgevy (TA1044) will define UK access to a functional cure. PFM · UK UK Spinal Muscular Atrophy Patient Flow Model A ~1,000-patient confirmed UK SMA cohort by type reconciles against a 1,800-2,000-patient total prevalence estimate. A 50-60/yr Zolgensma cohort is the on-therapy validation anchor. KOL · GCC GCC Fabry Disease KOL Mapping KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC. Its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it. P&HTA · UK UK Hereditary Angioedema Payer & HTA NICE TA606 recommended lanadelumab in 2019 with a confidential simple-discount patient access scheme, and the first national UK audit found total attacks fell 87.7% at 6 months. Berotralstat's TA738 recommendation is measured against that benchmark. MSM · US US Breast Cancer HR+/HER2- Market Sizing Model 316,950 annual US invasive breast cancer diagnoses and a 6.0% metastatic-at-diagnosis rate size the incident flow. Layering CDK4/6-inhibitor and post-progression pricing onto that flow, and onto the separate, larger recurrence pool, is what turns a patient count into a market value. MSM · US US Type 2 Diabetes Market Sizing Model IQVIA puts the 2023 US T2D drug market at $22B top-down. Triangulated bottom-up against 29.7M diagnosed patients out of 38.4M with the disease, the two methods converge, but per-class revenue split remains an open gap this model flags rather than invents. PFM · UK UK ATTR Amyloidosis Patient Flow Model True UK ATTRwt-CM prevalence runs 20,000-40,000, and 15,000-36,000 of those patients remain undiagnosed. Only 3,000-4,000 are on NHS-commissioned tafamidis today, adding 1,500-2,000 a year. LR · UK UK PNH Launch Readiness Ultomiris cannot resolve the EVH-dominant PNH population, and that gap defines the UK opportunity. Every PNH agent has now cleared the standard NICE Technology Appraisal bar; this sizes the PAS discount required to hit it before MHRA approval. PSM · GCC GCC Dravet Syndrome Pricing Strategy Model GCC Dravet pricing is an import-cost problem, not a rebate negotiation. Cannabidiol's Schedule-1-equivalent narcotics classification adds USD 10-15K in compassionate-programme cost plus SAR 5-8K in import logistics, while stiripentol's non-narcotic status keeps it at SAR 30-50K through standard hospital import. HTA · UK UK ATTR Amyloidosis HTA Strategy Model NICE recommends both ATTR-CM stabilisers, tafamidis (TA984) and acoramidis (TA1121), and directs clinicians to the cheaper one. Acoramidis cleared on indirect comparison alone. A third entrant must beat an invisible, PAS-discounted floor, with no published price target. PSM · US US IgA Nephropathy Pricing Strategy Model All five FDA-approved IgAN therapies clear the same prior-authorisation gate, not a negotiated rebate table. That gate is biopsy-confirmed diagnosis, UPCR 0.8-1.5 g/g, eGFR 30 or higher, and RAS-blockade step-through. No formal net-price data exists because access here runs on step-therapy criteria, not payer negotiation. PFM · GCC GCC Sickle Cell Disease Patient Flow Model 200,000-250,000 GCC sickle cell patients, with 140,000-200,000 in Saudi Arabia alone. NPHC's actively-managed registry reaches only 8,000-10,000 — the addressable near-term funnel stage within a much larger under-managed population, not a contradiction. PFM · US US Dravet Syndrome Patient Flow Model 6,000-8,000 US Dravet patients, roughly three-quarters SCN1A-confirmed. 35-40% are still inadequately controlled on cannabidiol plus fenfluramine, the population any new agent must actually reach. LR · US US NSCLC Launch Readiness Pembrolizumab holds an estimated 52% of first-line NSCLC on five years of precedent. Payers evaluate every new IO or targeted asset against KEYNOTE, CheckMate and IMpower coverage policy, not against a fresh trial design. MSM · US US Cold Agglutinin Disease Market Sizing Model US cold agglutinin disease sizing starts from a rate range, not a point estimate. Incidence 0.6-1.2 and 1-year prevalence 1.4-3.1 per 100,000 imply ~5,000 prevalent patients. No published treated-share figure exists to split served from total addressable. PSM · US US PNH Pricing Strategy Model Iptacopan's ~$550,000 annual WAC sits roughly 71% above ICER's $156,000-157,000 value-based benchmark. The orphan-drug exclusion keeps anti-C5 incumbents outside IRA's reach entirely. Those are the two forces any new US PNH entrant must price against. HTA · UK UK Spinal Muscular Atrophy HTA Strategy Model NICE built UK SMA access in sequence, not as an open field. Gene therapy took the pre-symptomatic subgroup first (HST15, HST24), then TA1162 moved chronic therapy to routine funding behind it. A new entrant inherits a fixed subgroup hierarchy and a comparator that shifts by population. HTA · UK UK Sickle Cell Disease HTA Strategy Model NICE recommended crizanlizumab (TA743) via managed access in 2021, then withdrew it in 2023 after the confirmatory trial failed. Casgevy (TA1044) cleared only by restructuring its £1.65M price into managed access. A new entrant inherits no reusable ICER benchmark from either. HTA · UK UK Hereditary Angioedema HTA Strategy Model Three completed NICE standard technology appraisals already fund HAE prophylaxis in England (TA606, TA738, TA1101). Every one cleared at the ordinary £20,000 to £30,000 per QALY bar and is held behind a confidential Patient Access Scheme, so a new entrant inherits a comparator-dense field in which garadacimab's £20,625 list pen is the only transparent price. DL · DE DE PNH Disease Landscape Germany has no confirmed PNH prevalence data of its own. The DGHO's Onkopedia guideline borrows an estimate from British and French registries, and diagnosis funnels through just two national referral centres. HTA · UK UK IgA Nephropathy HTA Strategy Model NICE accepted an eGFR-slope-to-ESRD-delay model, not headline proteinuria reduction, as the value basis in IgA nephropathy. That covers budesonide (TA937, expanded by TA1128) and sparsentan (TA1074). The mandatory ACEi/ARB and SGLT2 inhibitor optimisation gate narrows the UK's 10,000 to 15,000 patients to a 3,000 to 5,000 novel-agent-eligible pool before that pricing math applies. PFM · US US IgA Nephropathy Patient Flow Model 150,000 US IgA nephropathy patients, of whom 70,000-90,000 are biopsy-confirmed. Only 5,000-8,000 are on novel therapy today, while 15,000-25,000 patients with UPCR above 1g/g remain the addressable high-risk cohort this model sizes precisely. MSM · US US IgA Nephropathy Market Sizing Model An estimated 150,000 Americans have IgA nephropathy, but only 70,000-90,000 are biopsy-confirmed. Just 5,000-8,000 are on a disease-specific therapy today, within a 15,000-25,000-patient high-risk eligible cohort. CI · DE DE PNH Competitive Intelligence Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all. KOL · GCC GCC Sickle Cell Disease KOL Mapping Only three GCC institutions run structured adult sickle cell programmes for 200,000-250,000 patients. KFSH&RC, KAMC and AUH. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it. KOL · FR FR PNH KOL Mapping Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres. Only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it. KOL · US US Breast Cancer HR+/HER2- KOL Mapping A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data. MSM · US US MASH Market Sizing Model 6.7 million Americans have F2-F3 MASH, but Rezdiffra has already reported 42,250+ patients on therapy and $311.3M in Q1 2026 revenue. This model triangulates population against real uptake, not a modeled guess. MSM · GCC GCC PNH Market Sizing Model Saudi Arabia's rare disease registry counts about 400 confirmed PNH cases. Global prevalence rates, adjusted for the region's 25-50% consanguinity rate, imply a true GCC PNH population 20-30% higher, and fewer than 15 labs across six countries can even run the diagnostic test. PFM · US US Sickle Cell Disease Patient Flow Model An estimated 100,000 US sickle cell patients narrow to a 55,000-65,000-patient pool with no adequate novel therapy. Only 50-100 of the gene-therapy-eligible minority were actually treated in year one. PFM · UK UK Hereditary Angioedema Patient Flow Model The UK HAE Alliance counts 5,000-6,000 total patients, of whom 1,500-2,000 are on NICE-commissioned prophylaxis. A further 1,500-2,500 are attack-active but never treated, and Longhurst et al.'s 37-centre registry confirms 1,152 patients from the bottom up. PFM · US US Pompe Disease Patient Flow Model 5,000-10,000 Americans live with Pompe disease. Roughly 2,000 late-onset patients are on enzyme replacement therapy, and 375-600 of them, one in four, are inadequate responders, the subtype this model is built to size. PFM · DE DE PNH Patient Flow Model Germany has no domestic PNH prevalence count of its own. DGHO's Onkopedia guideline borrows a 16-per-million estimate from British and French registries, and only two national centres, Ulm and Essen, anchor referral. HTA · UK UK Fabry Disease HTA Strategy Model UK Fabry disease is commissioned through three different NICE and NHS routes at once. No formal technology appraisal for either enzyme replacement therapy, a Highly Specialised Technologies recommendation (HST4, 2016) for migalastat, and a standard appraisal (TA915, 2023) for pegunigalsidase alfa. A new entrant inherits no single reusable comparator or price benchmark. PSM · GCC GCC ATTR Amyloidosis Pricing Strategy Model GCC tafamidis pricing is not one number. Private-import pricing near SAR 820,000-850,000/year describes the pre-registration state; post-registration tender pricing near SAR 70,000-90,000 describes what follows. HTA · UK UK PNH HTA Strategy Model NICE has cleared all four modern PNH anti-complement therapies through its standard £20,000-30,000 Technology Appraisal route. Ravulizumab TA698, pegcetacoplan TA778, iptacopan TA1000 and crovalimab TA1019, each contingent on a confidential commercial arrangement, never the Highly Specialised Technologies threshold. A new submission inherits an unbroken standard-STA precedent it must be built to clear from the first dossier decision. PSM · GCC GCC Sickle Cell Disease Pricing Strategy Model At 200,000-250,000 GCC patients, US or UK list pricing is commercially impossible. NPHC's own exceptional-access threshold caps a novel agent near SAR 8,000-20,000/year, a fraction of a $2.2M gene-therapy WAC. MSM · GCC GCC Myasthenia Gravis Market Sizing Model GCC gMG sizing treats the 6,000-10,000-patient disease-landscape prevalence estimate as the authoritative broad base. A 200-300-patient refractory subgroup, fewer than 50 currently on a biologic, is the narrower actionable segment inside it, not a competing total. PSM · GCC GCC Pompe Disease Pricing Strategy Model NPHC's annual Pompe ERT budget runs SAR 100-160M across 80-120 patients. That is SAR 800K-1.2M for alglucosidase versus SAR 1.2-1.8M for avalglucosidase. A new entrant should target SAR 2.0-2.5M a year, with switch approvals clearing at only 40-60%. PSM · GCC GCC Myasthenia Gravis Pricing Strategy Model GCC gMG has no single price. Efgartigimod costs SAR 300,000-600,000/yr through private VHI, a different figure through hospital pharmacy committees, and a third through NPHC exceptional access, with a unified formulary price still 12-18 months out.